- Recommendation ID
- NG28/06
- Question
Effectiveness of SGLT2 inhibitors for adults with a urine ACR below 3 mg/mmol: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than 3 mg/mmol?
- Any explanatory notes
(if applicable) For a short explanation of why the committee made this recommendation for research, see the rationale on SGLT2 inhibitors for adults with type 2 diabetes and chronic kidney disease.
Full details of the evidence and the committee's discussion are in evidence review A: SGLT2 inhibitors for people with chronic kidney disease and type 2 diabetes.
Source guidance details
- Comes from guidance
- Type 2 diabetes in adults: management
- Number
- NG28
- Date issued
- December 2015
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 30/11/2021 |